文献速递衰弱、肌少症与跌倒多重用药老年慢病共病管理

降压试验对高龄患者的可推广性:横截面分析

Generalizability of Blood Pressure Lowering Trials to Older Patients: Cross-Sectional Analysis.
PubMed 文献 · J Am Geriatr Soc · 2020-09-08

该横截面研究基于英格兰24家全科诊所80岁及以上人群的匿名电子健康记录,评估既往两项药物强化试验(HYVET、SPRINT)和一项药物减量试验(OPTiMISE)的入选比例及特征。结果显示仅1.7%符合HYVET、34.4%符合SPRINT、25.6%符合OPTiMISE,衰弱、心血管多重用药和共病与入选可能性降低相关。

要点

  • 80岁及以上人群中仅1.7%符合HYVET入选标准,34.4%符合SPRINT,25.6%符合OPTiMISE。
  • 衰弱、心血管多重用药和共病与试验入选可能性降低相关。
  • 现有降压试验结果外推至衰弱或共病老人时需谨慎。

核心结论

  • 试图回答不同主要问题的降压试验所采用的血压标准,可能导致许多高龄患者缺乏试验证据来指导常规治疗决策。
  • 将现有试验结果应用于衰弱或共病患者时应谨慎。

研究设计与样本

  • 横截面研究,纳入英格兰24家全科诊所所有80岁及以上个体的匿名电子健康记录。
  • 共识别15,376名患者,评估符合HYVET、SPRINT和OPTiMISE试验入选标准的比例与特征。
  • 构建逻辑回归模型估计各试验入选的预测因素。

主要发现

  • 15,376名患者中,268名(1.7%;95%CI=1.5-2.0%)符合HYVET入选标准。
  • 5,290名(34.4%;95%CI=33.7-35.2%)符合SPRINT入选标准。
  • 3,940名(25.6%;95%CI=24.9-26.3%)符合OPTiMISE入选标准。
  • 各试验排除原因中,5.6%至30.7%是由于入选标准排除了高血压或未控制血压者。

关键数值与推荐

  • 符合HYVET入选标准者占1.7%(95%CI=1.5-2.0%)。
  • 符合SPRINT入选标准者占34.4%(95%CI=33.7-35.2%)。
  • 符合OPTiMISE入选标准者占25.6%(95%CI=24.9-26.3%)。

临床怎么用

  • 在常规实践中为高龄患者制定降压决策时,需认识到现有试验证据可能不适用于衰弱或共病人群。
  • 对衰弱、心血管多重用药或共病的老人,应用降压试验结果时应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Randomized controlled trials are used to inform clinical guidelines on the management of hypertension in older adults, but it is unclear to what extent these trials represent the general population attending routine clinical practice. This study aimed to define the proportion and characteristics of patients eligible for hypertension trials conducted in older people. DESIGN: Cross-sectional study. SETTING: A total of 24 general practices in England. PARTICIPANTS: Anonymized electronic health record data from all individuals aged 80 and older. MEASUREMENTS: Descriptive statistics were used to define the proportion and characteristics of patients eligible for two previous medication intensification trials (HYVET, SPRINT) and one medication reduction trial (OPTiMISE). A logistic regression model was constructed to estimate predictors of eligibility for each trial. RESULTS: Of 15,376 patients identified, 268 (1.7%; 95% confidence interval [CI] = 1.5-2.0%), 5,290 (34.4%; 95%CI = 33.7-35.2%), and 3,940 (25.6%; 95%CI = 24.9-26.3%) were eligible for the HYVET, SPRINT, and OPTiMISE trials, respectively. Between 5.6% and 30.7% of exclusions from each trial were due to eligibility criteria excluding those with high or uncontrolled blood pressure. Frailty (odds ratio [OR] = .44; 95%CI = .36-.54 [OPTiMISE]), cardiovascular polypharmacy (OR = .61; 95%CI = .55-.68 [SPRINT]) and multimorbidity (OR = .72; 95%CI = .64-.82 [SPRINT]) were associated with a lower likelihood of being eligible for one or more of the trials. CONCLUSION: A possible unintended consequence of blood pressure criteria used by trials attempting to answer different primary questions is that for many older patients, no trial evidence exists to inform treatment decisions in routine practice. Caution should be exercised when applying results from existing trials to patients with frailty or multimorbidity.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Sheppard JP, Lown M, Burt J, et al. Generalizability of Blood Pressure Lowering Trials to Older Patients: Cross-Sectional Analysis. J Am Geriatr Soc. 2020. PMID: 32898307. doi:10.1111/jgs.16749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。